2. Search Result
Search Result
Results for "

akinesia

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

1

Natural
Products

Art. -Nr. Produktname Target Forschungsgebiete Chemical Structure
  • HY-101357A
    CP 93129 dihydrochloride

    		5-HT Receptor Neurological Disease
    CP 93129 dihydrochloride is a potent 5HT1B receptor agonist. CP 93129 dihydrochloride has the potential for parkinson's disease research .
    CP 93129 dihydrochloride
  • HY-101357AR
    CP 93129 dihydrochloride (Standard)

    		Reference Standards 5-HT Receptor Neurological Disease
    CP 93129 (dihydrochloride) (Standard) is the analytical standard of CP 93129 (dihydrochloride). This product is intended for research and analytical applications. CP 93129 dihydrochloride is a potent 5HT1B receptor agonist. CP 93129 dihydrochloride has the potential for parkinson's disease research .
    CP 93129 dihydrochloride (Standard)
  • HY-11052A
    Trap-101 hydrochloride

    		Opioid Receptor Neurological Disease
    Trap-101 hydrochloride is a potent, selective and competitive antagonist of NOP receptors over classical opioid receptors. Trap-101 stimulates GTPγ 35S binding to CHOhNOP membranes with pKi values of 8.65, 6.60, 6.14 and <5 for NOP, μ-, κ-, and δ-opioid receptors, respectively. Trap-101 attenuates motor deficits in a rat model of parkinson's disease and can be used for the research of nervous system diseases .
    Trap-101 hydrochloride
  • HY-18654A
    ADX88178 TFA

    		mGluR Neurological Disease
    ADX88178 TFA is an orally active, blood-brain barrier-penetrant, selective positive allosteric modulator of mGluR4, with an EC50 of 3.5 nM against hmGluR4. ADX88178 TFA modulates mGlu4 activity, enhances glutamate-mediated receptor activation, and increases the apparent affinity of glutamate for the receptor. ADX88178 TFA reverses haloperidol-induced catalepsy, potentiates the effects of levodopa (L-DOPA) and quinpirole, but fails to alleviate established abnormal involuntary movements, does not exacerbate L-DOPA-induced dyskinesia, and does not affect forelimb akinesia when administered alone. ADX88178 TFA can be used in research related to L-DOPA-induced dyskinesia and Parkinson's disease .
    ADX88178 TFA
  • HY-N7773
    Hibiscetin

    		TNF Receptor Interleukin Related Caspase SOD Neurological Disease Metabolic Disease
    Hibiscetin is an orally active anti-inflammatory, antioxidant, antihyperglycemic, hypolipidemic, hepatoprotective and neuroprotective agent. Hibiscetin reduces the levels of TNF-α, IL-1β and IL-6. Hibiscetin inhibits lipid peroxidation, reduces MDA levels, and induces the activities of antioxidant enzymes CAT, GSH and SOD. Hibiscetin lowers blood glucose, reverses reduced insulin levels, regulates adipokine levels, and reduces elevated AST and ALT levels. Hibiscetin alleviates Rotenone (HY-B1756)-induced akinesia and catalepsy, normalizes neurotransmitter levels, and modulates the activities of activated caspase 3 and BDNF. Hibiscetin can be used in the research of type 2 diabetes, Parkinson's disease and Huntington's disease .
    Hibiscetin
  • HY-180422
    (-)-UH 232

    		Dopamine Receptor Neurological Disease
    (-)-UH 232 is a central dopamine (DA) receptor agonist. (-)-UH 232 weakly decreases 3, 4-dihydroxyphenylalanine (DOPA) formation in striatal and limbic brain regions in rats. (-)-UH 232 can be used for the research of neurological diseases including parkinson's disease and schizophrenia .
    (-)-UH 232

Online-Anfrage

Your information is safe with us. * Required Fields.

Anrede

  

Country or Region *

Name des Antragstellers *

 

Name der Organisation *

Department *

     

E-Mail-Addresse *

 

Produktname *

Art. -Nr.

  

Requested quantity *

Telefonnummer *

     

Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent: